Research Article

You have free access to this content

Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy

  1. Florence Legrand-Abravanel1,*,
  2. Philippe Colson2,
  3. Hélène Leguillou-Guillemette3,
  4. Laurent Alric4,
  5. Isabelle Ravaux5,
  6. Françoise Lunel-Fabiani3,
  7. Magali Bouviers-Alias6,
  8. Pascale Trimoulet7,
  9. Marie Laure Chaix8,
  10. Christophe Hézode9,
  11. Juliette Foucher10,
  12. Hélène Fontaine11,
  13. Anne-Marie Roque-Afonso12,
  14. Michèle Gassin13,
  15. Evelyne Schvoerer14,
  16. Catherine Gaudy15,
  17. Bruno Roche16,
  18. Michel Doffoël17,
  19. Louis D'Alteroche18,
  20. Sophie Vallet19,
  21. Yazid Baazia20,
  22. Bruno Pozzetto21,
  23. Vincent Thibault22,
  24. Jean-Baptiste Nousbaum23,
  25. Dominique Roulot24,
  26. Henry Coppere25,
  27. Thierry Poinard26,
  28. Christopher Payan19,
  29. Jacques Izopet1

Article first published online: 25 OCT 2009

DOI: 10.1002/jmv.21583

Issue

Journal of Medical Virology

Journal of Medical Virology

Volume 81, Issue 12, pages 2029–2035, December 2009

Additional Information

How to Cite

Legrand-Abravanel, F., Colson, P., Leguillou-Guillemette, H., Alric, L., Ravaux, I., Lunel-Fabiani, F., Bouviers-Alias, M., Trimoulet, P., Chaix, M. L., Hézode, C., Foucher, J., Fontaine, H., Roque-Afonso, A.-M., Gassin, M., Schvoerer, E., Gaudy, C., Roche, B., Doffoël, M., D'Alteroche, L., Vallet, S., Baazia, Y., Pozzetto, B., Thibault, V., Nousbaum, J.-B., Roulot, D., Coppere, H., Poinard, T., Payan, C. and Izopet, J. (2009), Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. J. Med. Virol., 81: 2029–2035. doi: 10.1002/jmv.21583

Author Information

  1. 1

    Laboratoire de virologie, Centre Hospitalier-Universitaire, Toulouse, France

  2. 2

    Laboratoire de virologie, Centre Hospitalier-Universitaire, Marseille, France

  3. 3

    Laboratoire de virologie, Centre Hospitalier-Universitaire, Angers, France

  4. 4

    Médecine interne, Centre Hospitalier-Universitaire, Toulouse, France

  5. 5

    Service de maladie infectieuse Centre Hospitalier-Universitaire, Marseille, France

  6. 6

    Laboratoire de virologie, Centre Hospitalier-Universitaire Mondor, Créteil, France

  7. 7

    Laboratoire de virologie, Centre Hospitalier-Universitaire, Bordeaux, France

  8. 8

    Laboratoire de virologie, Centre Hospitalier-Universitaire Necker, Paris, France

  9. 9

    Service de Gastroentérologie, Centre Hospitalier-Universitaire Mondor, Creteil, France

  10. 10

    Service de Gastroentérologie, Centre Hospitalier-Universitaire Bordeaux, France

  11. 11

    Service d'hépatologie Hôpital Cochin, Paris, France

  12. 12

    Laboratoire de virologie, Centre Hospitalier-Universitaire Paul Brousse, Paris, France

  13. 13

    Laboratoire de virologie, Centre Hospitalier-Universitaire, Nantes, France

  14. 14

    Laboratoire de virologie, Centre Hospitalier-Universitaire, Strasbourg, France

  15. 15

    Laboratoire de virologie, Centre Hospitalier-Universitaire, Tours, France

  16. 16

    Centre hépatobiliaire Centre Hospitalier-Universitaire, Paul-Brousse, Paris, France

  17. 17

    Service de Gastroentérologie Centre Hospitalier-Universitaire, Strasbourg, France

  18. 18

    Service de Gastroentérologie Centre Hospitalier-Universitaire, Tours, France

  19. 19

    Laboratoire de virologie, Centre Hospitalier-Universitaire, Brest, France

  20. 20

    Laboratoire de virologie, Centre Hospitalier-Universitaire Avicenne, Bobigny, France

  21. 21

    Laboratoire de virologie, Centre Hospitalier-Universitaire, Saint-Etienne, France

  22. 22

    Laboratoire de virologie, Centre Hospitalier-Universitaire Pitié-Salpétrière, Paris, France

  23. 23

    Service de Gastroentérologie, Centre Hospitalier-Universitaire, Brest, France

  24. 24

    Service de Gastroentérologie, Centre Hospitalier Jean Verdier, Bondy, France

  25. 25

    Service de Gastroentérologie Centre Hospitalier-Universitaire Saint-Etienne, France

  26. 26

    Service de Gastroentérologie Centre Hospitalier-Universitaire Pitié-Salpétrière, Paris, France

*330 Avenue de Grande Bretagne, TSA 40031, Toulouse 31059, France.

Publication History

  1. Issue published online: 25 OCT 2009
  2. Article first published online: 25 OCT 2009
  3. Manuscript Accepted: 26 MAY 2009

Funded by

  • Agence Nationale de Recherche Contre le SIDA et les Hepatites Virales (ANRS), AC11 HCV Study Group

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (89K)

REFERENCES

  • Bonny C, Fontaine H, Poynard T, Hezode C, Larrey D, Marcellin P, Bourliere M, Bronowicki JP, Merle P, Zarski JP, Sapey T, Guillemard C, Ughetto S, Henquell C, Nicolas C, Roche C, Randl K, Bommelaer G, Abergel A. 2006. Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study. Aliment Pharmacol Ther 24: 593–600.
    Direct Link:
  • Camma C, Bruno S, Schepis F, Lo Iacono O, Andreone P, Gramenzi AG, Mangia A, Andriulli A, Puoti M, Spadaro A, Freni M, Di Marco V, Cino L, Saracco G, Chiesa A, Crosignani A, Caporaso N, Morisco F, Rumi MG, Craxi A. 2002. Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: A meta-analysis of individual patient data. Gut 51: 864–869.
  • Cantaloube JF, Laperche S, Gallian P, Bouchardeau F, de Lamballerie X, de Micco P. 2006. Analysis of the 5′ noncoding region versus the NS5b region in genotyping hepatitis C virus isolates from blood donors in France. J Clin Microbiol 44: 2051–2056.
  • Chen Z, Weck KE. 2002. Hepatitis C virus genotyping: Interrogation of the 5′ untranslated region cannot accurately distinguish genotypes 1a and 1b. J Clin Microbiol 40: 3127–3134.
  • Dienstag JL, McHutchison J. 2006. American gastroenterological association technical review on the management of hepatitis C. Gastroenterology 130: 231–264.
  • Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, Lok AS, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Morishima C. 2006. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology (Baltimore, MD) 44: 1675–1684.
    Direct Link:
  • Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, Stauber R, Bischof M, Bauer B, Datz C, Loschenberger K, Formann E, Staufer K, Steindl-Munda P. 2008. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 135: 451–458.
  • Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975–982.
  • Fung J, Lai CL, Hung I, Young J, Cheng C, Wong D, Yuen MF. 2008. Chronic hepatitis C virus genotype 6 infection: Response to pegylated interferon and ribavirin. J Infect Dis 198: 808–812.
  • Hadziyannis SJ, Sette H, Jr., Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Jr., Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM. 2004. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346–355.
  • Hasan F, Asker H, Al-Khaldi J, Siddique I, Al-Ajmi M, Owaid S, Varghese R, Al-Nakib B. 2004. Peginterferon alfa-2b plus ribaririn for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol 99: 1733–1737.
    Direct Link:
  • Hui CK, Yuen MF, Sablon E, Chan AO, Wong BC, Lai CL. 2003. Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: A comparison with genotype 1. J Infect Dis 187: 1071–1074.
  • Kamal SM, El Tawil AA, Nakano T, He Q, Rasenack J, Hakam SA, Saleh WA, Ismail A, Aziz AA, Madwar MA. 2005. Peginterferon (alpha)-2b and ribavirin therapy in chronic hepatitisq C genotype 4: Impact of treatment duration and viral kinetics on sustained virological response. Gut 54: 858–866.
  • Krawitt EL, Ashikaga T, Gordon SR, Ferrentino N, Ray MA, Lidofsky SD. 2005. Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C. J Hepatol 43: 243–249.
  • Laperche S, Lunel F, Izopet J, Alain S, Deny P, Duverlie G, Gaudy C, Pawlotsky JM, Plantier JC, Pozzetto B, Thibault V, Tosetti F, Lefrere JJ. 2005. Comparison of hepatitis C virus NS5b and 5' noncoding gene sequencing methods in a multicenter study. J Clin Microbiol 43: 733–739.
  • Legrand-Abravanel F, Sandres-Saune K, Barange K, Alric L, Moreau J, Desmorat P, Vinel JP, Izopet J. 2004. Hepatitis C virus genotype 5: Epidemiological characteristics and sensitivity to combination therapy with interferon-alpha plus ribavirin. J Infect Dis 189: 1397–1400.
  • Legrand-Abravanel F, Nicot F, Boulestin A, Sandres-Saune K, Vinel JP, Alric L, Izopet J. 2005. Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. J Med Virol 77: 66–69.
    Direct Link:
  • Lindenbach BD, Rice CM. 2005. Unravelling hepatitis C virus replication from genome to function. Nature 436: 933–938.
  • Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 358: 958–965.
  • Martin-Carbonero L, Puoti M, Garcia-Samaniego J, De Luca A, Losada E, Quinzan G, Bruno R, Marino A, Gonzalez M, Nunez M, Soriano V. 2008. Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4. J Viral Hepat 15: 710–715.
    Direct Link:
  • McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339: 1485–1492.
  • Nicot F, Legrand-Abravanel F, Lafont T, Dubois M, Saune K, Pasquier C, Chatelut E, Izopet J. 2008. Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV. J Med Virol 80: 1523–1529.
    Direct Link:
  • Pittaluga F, Allice T, Abate ML, Ciancio A, Cerutti F, Varetto S, Colucci G, Smedile A, Ghisetti V. 2008. Clinical evaluation of the COBAS Ampliprep/COBAS TaqMan for HCV RNA quantitation in comparison with the branched-DNA assay. J Med Virol 80: 254–260.
    Direct Link:
  • Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. 1998. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352: 1426–1432.
  • Roulot D, Bourcier V, Grando V, Deny P, Baazia Y, Fontaine H, Bailly F, Castera L, De Ledinghen V, Marcellin P, Poupon R, Bourliere M, Zarski JP, Roudot-Thoraval F. 2007. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat 14: 460–467.
    Direct Link:
  • Sandres-Saune K, Deny P, Pasquier C, Thibaut V, Duverlie G, Izopet J. 2003. Determining hepatitis C genotype by analyzing the sequence of the NS5b region. J Virol Methods 109: 187–193.
  • Sarrazin C, Gartner BC, Sizmann D, Babiel R, Mihm U, Hofmann WP, von Wagner M, Zeuzem S. 2006. Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5. J Clin Microbiol 44: 729–737.
  • Serpaffi J, Chaix ML, Batisse D, Dupont C, Vallet-Pichard A, Fontaine H, Viard JP, Piketty C, Rouveix E, Rouzioux C, Weiss L, Pol S. 2006. Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1 infected men and inefficacy of early antiviral therapy. AIDS 20: 233–240.
  • Sherman M, Yoshida EM, Deschenes M, Krajden M, Bain VG, Peltekian K, Anderson F, Kaita K, Simonyi S, Balshaw R, Lee SS. 2006. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut 55: 1631–1638.
  • Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, Halfon P, Inchauspe G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin IT, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A. 2005. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology (Baltimore, MD) 42: 962–973.
    Direct Link:
  • Sulkowski M, Lawitz E, Shiffman ML, Muir AJ, Galler G, McCone J, Nyberg LM, Lee W, Ghalib R, Schiff E, Galati J, Bacon B, Davis M, Mukhopadhyay P, Noviello v, Pedicone L, Albrecht J, McHutchison J. 2008. Final results of the IDEAL (Individualised dosing efficacy versus flat dosing to assess optimal pegylated interferon therapy) phase IIIB study. J Hepatol 48: S370–S371.
  • Vermehren J, Kau A, Gartner BC, Gobel R, Zeuzem S, Sarrazin C. 2008. Differences between two real-time PCR based assays (RealTime HCV, COBAS AmpliPrep/COBAS TaqMan) and one signal amplification assay (VERSANT HCV RNA 3.0) for HCV RNA detection and quantification. J Clin Microbiol 16: 3880–3891.
  • Vispo E, Barreiro P, Rodriguez-Novoa S, Morello J, Labarga P, Martin-Carbonero L, Maida I, Garcia-Gasco P, Soriano V. 2008. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b. Antivir Ther 13: 511–517.
  • Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, Lee LP, Hsieh MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL. 2008. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial. Hepatology (Baltimore, MD) 47: 1884–1893.
    Direct Link:
  • Zeuzem S. 2004. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: Who responds less well? Ann Intern Med 140: 370–381.
  • Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, Ibranyi E, Weiland O, Noviello S, Brass C, Albrecht J. 2006. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 44: 97–103.
Get PDF (89K)